Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection of DNA into tissue, although safer than viral vectors, ...
The success of gene therapy depends on reaching adequate levels and duration of transgene expression in a target organ or tissue. When the therapeutic gene is toxic, this requirement needs to be ...
To the Editor: Mannon et al. (Nov. 11 issue) 1 describe the safety of anti–interleukin-12 antibody (anti–interleukin-12) for the treatment of active Crohn's disease. Among the 44 recipients of ...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies ...
Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program. This program is the early-stage ...
No single definition of cytokine storm or the cytokine release syndrome is widely accepted, and there is disagreement about how these disorders differ from an appropriate inflammatory response. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback